QM · rank #20 · 2026-10-23
ETON
NASDAQ · $1.43B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +180.43% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +36.0% |
| Profit margin Net profit margin, trailing 12 months. | +12.0% |
| Market cap (USD) Size filter: > $500M required. | $1.43B |
| Anchor (recent) Close on 2026-09-23 | $55.61 |
| Anchor (far) Close on 2025-09-23 | $19.83 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Eton Pharmaceuticals is a rare-disease commercialization platform with eleven commercial products built on exclusive licensed rights, orphan-drug positioning, and dedicated patient-access infrastructure rather than a proprietary patent moat.
Rationale
The momentum_12_1 of 1.80 reflects a near-doubling of revenue YoY and a guidance raise to $145M+, while ROE of 36% and a 12% profit margin confirm the quality screen is anchored in real, improving fundamentals rather than sentiment alone.
Material risks
- 1LIBERVANT and IMPAVIDO are licensed/exclusive-rights products, not owned IP — loss, renegotiation, or supply disruption of either could materially collapse the revenue base that is driving both the momentum and quality signals.
- 2LIBERVANT still requires final FDA approval before an April 2027 launch, and AMGLIDIA's NDA is pending year-end 2026 submission, meaning a meaningful portion of the guided $145M+ trajectory carries binary regulatory execution risk.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.